Drugs of Abuse Testing Assays
6-Acetylmorphine
AB-PINACA
- ARK AB-PINACA Assay
- Immunalysis Synthetic Cannabinoids-3 HEIA
Amphetamines
- Immunalysis Amphetamines HEIA
Barbiturates
- Immunalysis Barbiturates HEIA
Benzodiazepines
Benzoylecgonine (Cocaine Metab.)
- Immunalysis Benzoylecgonine HEIA
Buprenorphine
Cannabinoids
- Immunalysis Cannabinoids HEIA
Carisoprodol
- Immunalysis Carisoprodol HEIA
EDDP
- ARK EDDP Assay
- Immunalysis EDDP Specific HEIA
Ethylglucuronide (EtG)
Fentanyl
JWH-018
- ARK UR144/JWH-018 Assay
- Immunalysis Synthetic Cannabinoids-1 HEIA
Ketamine
Meperidine
- ARK Meperidine Assay
- Immunalysis Meperidine HEIA
Methamphetamine
- Immunalysis Methamphetamine HEIA
Methylphenidate-Metabolite
Opiates
- Immunalysis Opiates HEIA
Oxycodone
- Immunalysis Oxycodone HEIA
Phencyclidine (PCP)
- Immunalysis Phencyclidine HEIA
Pregabalin
Tapentadol
- Immunalysis Tapentadol HEIA
Tramadol
- ARK Diagnostics Tramadol Assay
- Immunalysis Tramadol HEIA
UR-144 / XLR-11
- ARK UR144/JWH-018 Assay
- Immunalysis Synthetic Cannabinoids-2 HEIA
Zolpidem
- Immunalysis Zolpidem HEIA
EDDP Specific Urine HEIA
The EDDP Specific Urine HEIA adds another highly specific assay to our extensive range of homogeneous enzyme immunoassays. With its sensitive and highly specific method, you can reliably detect the methadone metabolite EDDP (2-ethylidine-1,5-dimethyl-3,3-diphenyl-pyrrolidine).
Assay Characteristics
- Highly sensitive and specific method to detect EDDP in urine
- Distinct cut-offs: 100 ng/mL, 300 ng/mL & 1000 ng/mL for qualitative and 100 ng/mL & 300 ng/mL for semi-quantitative analysis
- Liquid, stable, ready-to-use reagents, calibrators, and controls – no reconstitution required
- Application protocols available for all major clinical chemistry analyzers
- Flexible kit sizes for your laboratory’s individual needs
Background
Methadone is a synthetic substance initially developed as an alternative to morphine and has similar pharmacological properties to heroin and morphine. However, at a stable dosage, it leads to significantly lower levels of euphoria or intoxication. Substitution programs with methadone have proven to be very effective in the treatment of heroin addiction.
However, monitoring patient compliance using methadone immunoassays has some significant drawbacks. These include, above all, the dependence of renal methadone clearance on the pH value of the urine. Alkaline urine (pH = >7) can significantly reduce the renal clearance of unmetabolized methadone. In substitution programs, this can lead to problems if a urine sample does not contain sufficient methadone for a positive drug test. As a negative result seems to indicate that the patient has not taken the allocated dose, this could lead to exclusion from the program. In contrast, the renal clearance of EDDP is unaffected by alkaline urine. If EDDP can be detected, patient compliance is assured.
On the other hand, if a patient attempts to feign compliance by adding a small amount of methadone to their own urine to obtain a positive methadone result, an EDDP test again clearly proves that this patient has not taken their dose. Finally, the EDDP assay also makes it possible to identify people who are taking their methadone dose but are trying to conceal co-use by mixing a small amount of methadone into another person’s urine sample.
The EDDP Specific Urine Assay can be used as a supplement to methadone screening or as a substitute for such screening. It not only facilitates the detection of compliance but also helps rule out possible manipulation of urine samples.
Package Inserts